(Q38271881)

1 September 2017

1 reference

title

Anti-TNF therapeutics for the treatment of sarcoidosis (English)

1 reference

1 September 2017

0 references

0 references

Heleen A Crommelin

1

1 reference

1 September 2017

Adriane D M Vorselaars

2

1 reference

1 September 2017

Coline H M van Moorsel

3

1 reference

1 September 2017

Ingrid H E Korenromp

4

1 reference

1 September 2017

Vera H M Deneer

5

1 reference

1 September 2017

Jan C Grutters

6

1 reference

1 September 2017

publication date

1 January 2014

1 reference

1 September 2017

1 reference

1 September 2017

volume

6

1 reference

1 September 2017

issue

10

1 reference

1 September 2017

page(s)

1127-1143

1 reference

1 September 2017

1 reference

21 January 2018

Statement on Sarcoidosis

1 reference

21 January 2018

1 reference

Sarcoidosis - a clinically orientated review

21 January 2018

1 reference

Clinical characteristics of patients in a case control study of sarcoidosis

21 January 2018

1 reference

A concise review of pulmonary sarcoidosis

21 January 2018

1 reference

Extrapulmonary manifestations of sarcoidosis.

21 January 2018

1 reference

Diagnosis of pulmonary sarcoidosis

21 January 2018

1 reference

Diagnostic criteria for sarcoidosis

21 January 2018

1 reference

Epidemiology of sarcoidosis in Japan.

21 January 2018

1 reference

Sarcoidosis in black women in the United States: data from the Black Women's Health Study

21 January 2018

1 reference

Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization

21 January 2018

1 reference

A worldwide review of sarcoidosis

21 January 2018

1 reference

Sarcoidosis mortality in the United States 1979-1991: an analysis of multiple-cause mortality data.

21 January 2018

1 reference

21 January 2018

1 reference

Course and prognosis of sarcoidosis around the world

21 January 2018

1 reference

Single-cell analysis: a novel approach to tumour necrosis factor-alpha synthesis and secretion in sarcoidosis

21 January 2018

1 reference

Immunologic response of sarcoidosis

21 January 2018

1 reference

Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics

21 January 2018

1 reference

On the nature of sarcoidosis

21 January 2018

1 reference

Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS).

21 January 2018

1 reference

Pathogenesis of sarcoidosis

21 January 2018

1 reference

Pulmonology meets rheumatology in sarcoidosis: a review on the therapeutic approach.

21 January 2018

1 reference

Treatments for pulmonary sarcoidosis

21 January 2018

1 reference

Corticosteroid treatment in sarcoidosis

21 January 2018

1 reference

Early treatment of stage II sarcoidosis improves 5-year pulmonary function

21 January 2018

1 reference

Current therapy in sarcoidosis, the role of existing drugs and future medicine

21 January 2018

1 reference

Methotrexate vs azathioprine in second-line therapy of sarcoidosis

21 January 2018

1 reference

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

21 January 2018

1 reference

The tumor necrosis factor ligand and receptor families.

21 January 2018

1 reference

Characterization of tumor necrosis factor-deficient mice

21 January 2018

1 reference

TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection

21 January 2018

1 reference

Influence of repeated maximal exercise testing on biomarkers and fatigue in sarcoidosis

21 January 2018

1 reference

Associations between TNF-α -308 A/G and lymphotoxin-α +252 A/G polymorphisms and susceptibility to sarcoidosis: a meta-analysis.

21 January 2018

1 reference

The role of tumor necrosis factor alpha G-308A polymorphisms in the course of pulmonary sarcoidosis

21 January 2018

1 reference

Role of genetic polymorphisms in ACE and TNF-alpha gene in sarcoidosis: a meta-analysis

21 January 2018

1 reference

Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients

21 January 2018

1 reference

Thalidomide for chronic sarcoidosis

21 January 2018

1 reference

Treatment of cutaneous sarcoidosis with thalidomide

21 January 2018

1 reference

Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids

21 January 2018

1 reference

Efficacy and safety of apremilast in chronic cutaneous sarcoidosis.

21 January 2018

1 reference

Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis

21 January 2018

1 reference

Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement

21 January 2018

1 reference

Long-term treatment with infliximab in patients with sarcoidosis

21 January 2018

1 reference

Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy.

21 January 2018

1 reference

A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis

21 January 2018

1 reference

Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis

21 January 2018

1 reference

Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages.

21 January 2018

1 reference

Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages

21 January 2018

1 reference

Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone

21 January 2018

1 reference

The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial.

21 January 2018

1 reference

Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation

21 January 2018

1 reference

Treatment of refractory neurosarcoidosis with Infliximab.

21 January 2018

1 reference

Medically refractory neurosarcoidosis treated with infliximab

21 January 2018

1 reference

Osseous sarcoidosis treated with tumor necrosis factor-inhibitors: case report and review of the literature

21 January 2018

1 reference

Effect of the TNF-α inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET.

21 January 2018

1 reference

Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report

21 January 2018

1 reference

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls

21 January 2018

1 reference

Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents

21 January 2018

1 reference

Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases

21 January 2018

1 reference

TNF receptor 2 pathway: drug target for autoimmune diseases

21 January 2018

1 reference

Two tumour necrosis factor receptors: structure and function.

21 January 2018

1 reference

Differential expression of TNFR1 (CD120a) and TNFR2 (CD120b) on subpopulations of human monocytes

21 January 2018

1 reference

Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha

21 January 2018

1 reference

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

21 January 2018

1 reference

Clinical pharmacokinetics of TNF antagonists: how do they differ?

21 January 2018

1 reference

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

Adverse events of tumor necrosis factor inhibitors

21 January 2018

1 reference

Treatment of sarcoidosis with infliximab

21 January 2018

1 reference

Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients

21 January 2018

1 reference

Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance

21 January 2018

1 reference

Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease.

21 January 2018

1 reference

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

21 January 2018

1 reference

Population pharmacokinetics of infliximab in patients with ankylosing spondylitis

21 January 2018

1 reference

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab

21 January 2018

1 reference

Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease

21 January 2018

1 reference

New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication

21 January 2018

1 reference

Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases

21 January 2018

1 reference

Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy

21 January 2018

1 reference

Clinical outcomes in sarcoidosis after cessation of infliximab treatment

21 January 2018

1 reference

Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis

21 January 2018

1 reference

Characterization of chronic fatigue in patients with sarcoidosis in clinical remission

21 January 2018

1 reference

Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis.

21 January 2018

1 reference

Imaging the inflammatory activity of sarcoidosis

21 January 2018

1 reference

The role of the PET scan in the management of sarcoidosis

21 January 2018

1 reference

Biomarkers for prediction of TNFalpha blockers response in rheumatoid arthritis

21 January 2018

1 reference

Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis

21 January 2018

1 reference

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

21 January 2018

1 reference

Changes in disease activity, lung function and quality of life in patients with refractory sarcoidosis after anti-TNF treatment

21 January 2018

1 reference

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.14.65

1 reference

1 September 2017

1 reference